Kunjin replicon-based simian immunodeficiency virus gag vaccines

Vaccine

Volumn 26, Issue 26, 2008, Pages 3268-3276

  Anraku, Itaru ^a   Mokhonov, Vladislav V ^b   Rattanasena, Paweena ^a   Mokhonova, Ekaterina I ^b   Leung, Jason ^b   Pijlman, Gorben ^b   Cara, Andrea ^c   Schroder, Wayne A ^a   Khromykh, Alexander A ^b   Suhrbier, Andreas ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Replicon; SIV; Vaccine

Indexed keywords

GAG PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; SIV GAG DX PROTEIN; SIV GAG OPT PROTEIN; SIV GAG POL PROTEIN; SIV GAG WT PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CODON; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE CONSTRUCT; GENE DELIVERY SYSTEM; GENE INDUCTION; IMMUNOGENICITY; KUNJIN VIRUS; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; REPLICON; RNA SEQUENCE; RNA VECTOR; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURAL GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS LIKE AGENT;

ANIMALS; FEMALE; GENE PRODUCTS, GAG; GENETIC VECTORS; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; REPLICON; SAIDS VACCINES; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; WEST NILE VIRUS;

EID: 44749093424     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.001     Document Type: Article

References (69)

1. Nakaya Y., Zheng H., and Garcia-Sastre A. Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants. Vaccine 21 (2003) 2097-2106
2. Nakaya Y., Nakaya T., Park M.S., Cros J., Imanishi J., Palese P., et al. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J Virol 78 (2004) 9366-9375
3. von Messling V., and Cattaneo R. Toward novel vaccines and therapies based on negative-strand RNA viruses. Curr Top Microbiol Immunol 283 (2004) 281-312
4. Griesenbach U., Inoue M., Hasegawa M., and Alton E.W. Sendai virus for gene therapy and vaccination. Curr Opin Mol Ther 7 (2005) 346-352
5. Eriksson K.K., Makia D., Maier R., Ludewig B., and Thiel V. Towards a coronavirus-based HIV multigene vaccine. Clin Dev Immunol 13 (2006) 353-360
6. Negri D.R., Michelini Z., Baroncelli S., Spada M., Vendetti S., Buffa V., et al. Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 15 (2007) 1716-1723
7. Johnston R.E., Johnson P.R., Connell M.J., Montefiori D.C., West A., Collier M.L., et al. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 23 (2005) 4969-4979
8. Cecil C., West A., Collier M., Jurgens C., Madden V., Whitmore A., et al. Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles. Virology 362 2 (2007) 362-373
9. Kong W., Tian C., Liu B., and Yu X.F. Stable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic sindbis virus vector. J Virol 76 (2002) 11434-11439
10. Anderson M.J., Porter D.C., Moldoveanu Z., Fletcher III T.M., McPherson S., and Morrow C.D. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res Hum Retroviruses 13 (1997) 53-62
11. Harvey T.J., Anraku I., Linedale R., Harrich D., Mackenzie J., Suhrbier A., et al. Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J Virol 77 (2003) 7796-7803
12. Pijlman G.P., Suhrbier A., and Khromykh A.A. Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther 6 (2006) 135-145
13. Hall R.A., Broom A.K., Smith D.W., and Mackenzie J.S. The ecology and epidemiology of Kunjin virus. Curr Top Microbiol Immunol 267 (2002) 253-269
14. Harvey T.J., Liu W.J., Wang X.J., Linedale R., Jacobs M., Davidson A., et al. Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol 78 (2004) 531-538
15. Anraku I., Harvey T.J., Linedale R., Gardner J., Harrich D., Suhrbier A., et al. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol 76 (2002) 3791-3799
16. von Gegerfelt A.S., Rosati M., Alicea C., Valentin A., Roth P., Bear J., et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 81 (2007) 1972-1979
17. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80 (2006) 5875-5885
18. Mattapallil J.J., Douek D.C., Buckler-White A., Montefiori D., Letvin N.L., Nabel G.J., et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 203 (2006) 1533-1541
19. Suh Y.S., Park K.S., Sauermann U., Franz M., Norley S., Wilfingseder D., et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 24 (2006) 1811-1820
20. Sacha J.B., Chung C., Rakasz E.G., Spencer S.P., Jonas A.K., Bean A.T., et al. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 178 (2007) 2746-2754
21. Kawada M., Tsukamoto T., Yamamoto H., Takeda A., Igarashi H., Watkins D.I., et al. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J Virol 81 (2007) 5202-5211
22. Schneider R., Campbell M., Nasioulas G., Felber B.K., and Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71 (1997) 4892-4903
23. Hel Z., Tsai W.P., Thornton A., Nacsa J., Giuliani L., Tryniszewska E., et al. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 167 (2001) 7180-7191
24. Zhao J., Lou Y., Pinczewski J., Malkevitch N., Aldrich K., Kalyanaraman V.S., et al. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine 21 (2003) 4022-4035
25. Zolotukhin A.S., Michalowski D., Bear J., Smulevitch S.V., Traish A.M., Peng R., et al. PSF acts through the human immunodeficiency virus type 1 mRNA instability elements to regulate virus expression. Mol Cell Biol 23 (2003) 6618-6630
26. Schwartz S., Felber B.K., and Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 66 (1992) 150-159
27. Liu W.J., Zhao K.N., Gao F.G., Leggatt G.R., Fernando G.J., and Frazer I.H. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20 (2001) 862-869
28. Davies M.N., and Flower D.R. Harnessing bioinformatics to discover new vaccines. Drug Discov Today 12 (2007) 389-395
29. Bolesta E., Gzyl J., Wierzbicki A., Kmieciak D., Kowalczyk A., Kaneko Y., et al. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens. Virology 332 (2005) 467-479
30. Varnavski A.N., Young P.R., and Khromykh A.A. Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol 74 (2000) 4394-4403
31. Kestler H., Kodama T., Ringler D., Marthas M., Pedersen N., Lackner A., et al. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248 (1990) 1109-1112
32. Negri D.R., Buffa V., Leone P., Bona R., Borghi M., Carlini F., et al. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. J Immunol Methods 291 (2004) 153-163
33. Westaway E.G., Mackenzie J.M., Kenney M.T., Jones M.K., and Khromykh A.A. Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol 71 (1997) 6650-6661
34. Macdonald J., Tonry J., Hall R.A., Williams B., Palacios G., Ashok M.S., et al. NS1 protein secretion during the acute phase of West Nile virus infection. J Virol 79 (2005) 13924-13933
35. Miroux B., and Walker J.E. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J Mol Biol 260 (1996) 289-298
36. Le T.T., Drane D., Malliaros J., Cox J.C., Rothel L., Pearse M., et al. Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine 19 (2001) 4669-4675
37. Elliott S.L., Pye S., Le T., Mateo L., Cox J., Macdonald L., et al. Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. Vaccine 17 (1999) 2009-2019
38. Someya K., Xin K.Q., Matsuo K., Okuda K., Yamamoto N., and Honda M. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 78 (2004) 9842-9853
39. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 (2004) 6290-6297
40. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80 (2006) 4717-4728
41. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 10 (2004) 406-410
42. Godkin A.J., Thomas H.C., and Openshaw P.J. Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. J Immunol 169 (2002) 2210-2214
43. Spaulding A.C., Kurane I., Ennis F.A., and Rothman A.L. Analysis of murine CD8(+) T-cell clones specific for the Dengue virus NS3 protein: flavivirus cross-reactivity and influence of infecting serotype. J Virol 73 (1999) 398-403
44. Tscharke D.C., and Suhrbier A. From mice to humans-murine intelligence for human CD8+ T cell vaccine design. Expert Opin Biol Ther 5 (2005) 263-271
45. Molinier-Frenkel V., Gahery-Segard H., Mehtali M., Le Boulaire C., Ribault S., Boulanger P., et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 74 (2000) 7678-7682
46. Fayzulin R., Scholle F., Petrakova O., Frolov I., and Mason P.W. Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines. Virology 351 (2006) 196-209
47. Coupar B.E., Purcell D.F., Thomson S.A., Ramshaw I.A., Kent S.J., and Boyle D.B. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 24 (2006) 1378-1388
48. Kent S.J., Hu S.L., Corey L., Morton W.R., and Greenberg P.D. Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J Virol 70 (1996) 4941-4947
49. Kriajevska M.V., Zakharova L.G., and Altstein A.D. Genetic instability of vaccinia virus containing artificially duplicated genome regions. Virus Res 31 (1994) 123-137
50. Junker U., Bohnlein E., and Veres G. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy. Gene Ther 2 (1995) 639-646
51. Lee S.G., Kim D.Y., Hyun B.H., and Bae Y.S. Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system. J Virol 76 (2002) 1649-1662
52. Dufresne A.T., Dobrikova E.Y., Schmidt S., and Gromeier M. Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sites. J Virol 76 (2002) 8966-8972
53. Raju R., Subramaniam S.V., and Hajjou M. Genesis of Sindbis virus by in vivo recombination of nonreplicative RNA precursors. J Virol 69 (1995) 7391-7401
54. Valadkhan S. The spliceosome: caught in a web of shifting interactions. Curr Opin Struct Biol 17 (2007) 310-315
55. Swanson C.M., Puffer B.A., Ahmad K.M., Doms R.W., and Malim M.H. Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J 23 (2004) 2632-2640
56. Mescher M.F., Curtsinger J.M., Agarwal P., Casey K.A., Gerner M., Hammerbeck C.D., et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211 (2006) 81-92
57. Liu A., Guardino A., Chinsangaram L., Goldstein M.J., Panicali D., and Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand. Cancer Res 67 (2007) 7037-7044
58. Fuchs E.J., and Matzinger P. Is cancer dangerous to the immune system?. Semin Immunol 8 (1996) 271-280
59. Vaccari M., Trindade C.J., Venzon D., Zanetti M., and Franchini G. Vaccine-induced CD8+ central memory T cells in protection from simian AIDS. J Immunol 175 (2005) 3502-3507
60. Altes H.K., Price D.A., and Jansen V.A. Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV. Vaccine 20 (2001) 3-6
61. Jansen C.A., van Baarle D., and Miedema F. HIV-specific CD4+ T cells and viremia: who's in control?. Trends Immunol 27 (2006) 119-124
62. Brown K., Gao W., Alber S., Trichel A., Murphey-Corb M., Watkins S.C., et al. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 171 (2003) 6875-6882
63. Brandt S., Blissenbach M., Grewe B., Konietzny R., Grunwald T., and Uberla K. Rev proteins of human and simian immunodeficiency virus enhance RNA encapsidation. PLoS Pathog 3 (2007) e54
64. Zhu Y., Koo K., Bradshaw J.D., Sutton W.F., Kuller L.R., Bucala R., et al. Macaque blood-derived antigen-presenting cells elicit SIV-specific immune responses. J Med Primatol 29 (2000) 182-192
65. Brandt S., Grunwald T., Lucke S., Stang A., and Uberla K. Functional replacement of the R region of simian immunodeficiency virus-based vectors by heterologous elements. J Gen Virol 87 (2006) 2297-2307
66. McDonald D., Vodicka M.A., Lucero G., Svitkina T.M., Borisy G.G., Emerman M., et al. Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 159 (2002) 441-452
67. Martin-Serrano J., Zang T., and Bieniasz P.D. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 7 (2001) 1313-1319
68. Pfeiffer T., Pisch T., Devitt G., Holtkotte D., and Bosch V. Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells. FEBS Lett 580 (2006) 3775-3778
69. Moses A.V., Stenglein S.G., Strussenberg J.G., Wehrly K., Chesebro B., and Nelson J.A. Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region on the viral genome. J Virol 70 (1996) 3401-3406